Dr. Mark Treherne, PhD ​
Science Advisory Board Member

Mark Treherne, Ph.D., is a neuroscientist, life-sciences entrepreneur and company director with more than 30 years of experience spanning neuroscience, drug discovery, company formation, investment and therapeutic development.

​

Dr. Treherne earned his Ph.D. in Pharmacology from the University of Cambridge. He subsequently joined Pfizer, where he contributed to research on neurodegenerative diseases across the United Kingdom and Europe.

​

In 1997, he co-founded Cambridge Drug Discovery and served as its Chief Executive. The company was subsequently acquired by a publicly listed company in 2001. Since then, Dr. Treherne has helped life-sciences companies raise investment, build development strategies and achieve successful exits. He has served on the boards of therapeutics, diagnostics and research-services companies operating internationally.

​

From 2012 to 2016, Dr. Treherne led UK Trade and Investment’s Life Sciences Organisation, supporting international investment into the United Kingdom and helping British life-sciences companies develop opportunities in global markets. He also served as a Council Member of Innovate UK.

​

His scientific interests include neuroscience, digital biomarkers, data science and the use of predictive models to improve decision-making in therapeutic development. He has particularly focused on strengthening the predictive value of preclinical disease models to support the development of safer and more effective medicines.

​

At SMDG, Dr. Treherne contributes expertise in neuroscience, drug discovery, company development, investment strategy and the translation of scientific innovation as a member of the Science Advisory Board.